CAY10499: Precision Inhibitor of Human Hormone Sensitive Lipase in Lipid Metabolism Research

Principle Overview: Targeting Lipid Mobilization and Metabolic Signaling

Lipid metabolism is central to cellular energy homeostasis and underpins diverse physiological processes—from adipose tissue lipolysis and steroidogenesis to immune cell differentiation and tumor microenvironment remodeling. At the heart of these pathways, hormone sensitive lipase (HSL) and monoglyceride lipase (MGL) orchestrate the hydrolysis of stored triacylglycerols and the turnover of key signaling lipids such as 2-arachidonoylglycerol (2-AG). CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase, is a crystalline small molecule engineered for high selectivity and nanomolar potency, enabling researchers to interrogate lipid metabolic fluxes and their downstream functional consequences in health and disease contexts.

Unlike broader-spectrum lipase inhibitors, CAY10499 offers robust selectivity: it blocks recombinant human HSL with an IC₅₀ of 90 nM, MGL-mediated hydrolysis of 4-nitrophenyl acetate at 0.5 ± 0.03 μM, and inhibits FAAH-catalyzed hydrolysis with an IC₅₀ of 76 nM, while showing minimal off-target activity at CB1/CB2 cannabinoid receptors according to the product information. This profile makes it an ideal lipid metabolism assay reagent for studies ranging from fatty acid mobilization to immunometabolism and atherosclerosis modeling.

Step-by-Step Workflow: Assay Design and Experimental Implementation

Integrating CAY10499 into lipid metabolism experiments requires careful consideration of solubility, dosing, and compatibility with downstream analytical platforms. Below, we outline recommended experimental steps for both biochemical and cell-based applications, drawing from both manufacturer data and published research:

Protocol Parameters

• Stock solution preparation: Dissolve CAY10499 at 10–30 mM in DMSO (solubility ≥32.4 mg/mL); aliquot and store at –20°C for up to 6 months.
• Working concentration range: Use 0.1–1 μM for HSL/MGL inhibition in biochemical assays; titrate to 0.5–5 μM for cell-based lipid hydrolysis or fatty acid mobilization studies, minimizing DMSO to <0.5% v/v in final assay media.
• Incubation time: Preincubate with CAY10499 for 10–30 minutes at 37°C prior to substrate addition or stimulus in enzyme or cell-based assays.

In cell culture, CAY10499 can be added directly to serum-free or low-serum media to block lipolytic responses (e.g., in adipocytes, macrophages, or hepatocytes), or in conjunction with lipid tracers (e.g., [³H]-glycerol release, BODIPY-labeled lipids) to quantify blockade of triacylglycerol breakdown. For immunometabolic studies, its use enables precise dissection of lipid signaling contributions to macrophage polarization, as detailed in recent studies linking lipid metabolism to immune suppression in cancer.

Key Innovation from the Reference Study

The reference study introduces a paradigm-shifting model of tumor microenvironment manipulation, showing that hepatocellular carcinoma (HCC) cells secrete extracellular vesicles (EVs) loaded with ATP-citrate lyase (ACLY) that are preferentially taken up by monocytes, reprogramming them into immunosuppressive tumor-associated macrophages (TAMs). This metabolic re-education is driven by EV-transferred ACLY, which enhances lipid biosynthetic pathways—especially palmitoylation—thereby stabilizing immune checkpoint proteins and fueling tumor immune evasion. Notably, the study demonstrates that targeted inhibition of this axis (using liposomal vesicles loaded with an ACLY inhibitor) reduces TAM-mediated immune suppression and enhances immunotherapeutic outcomes in HCC models.

For researchers utilizing CAY10499, these findings underscore the power of targeting lipid metabolic enzymes not just for classic metabolic readouts, but for manipulating immune cell fate and the tumor microenvironment. Incorporating a potent HSL inhibitor such as CAY10499 enables precise evaluation of alternative or complementary lipid pathways in TAM differentiation, particularly when modeling the crosstalk between lipid hydrolysis, fatty acid availability, and immunoregulatory signaling in tumor or inflammation settings.

Advanced Applications and Comparative Advantages

Beyond classic lipolysis assays, CAY10499 has emerged as a critical research tool for:

• Inhibitor for steroidogenesis research: By blocking HSL-catalyzed cholesterol ester hydrolysis, CAY10499 facilitates studies into hormone biosynthesis and its dysregulation in endocrine and metabolic disorders.
• Research tool for atherosclerosis: In foam cell models, HSL inhibition helps dissect the contribution of lipid droplet mobilization to plaque formation and regression.
• Enzyme inhibitor for fatty acid mobilization studies: Selective blockade of HSL and MGL activity allows for mapping the interplay between stored triglyceride pools and rapid lipid signaling events in immune and non-immune cells.

As highlighted in "CAY10499: Applied Inhibitor for Human Hormone Sensitive Lipase Assays", this compound delivers robust performance across varied assay platforms, supporting both high-throughput and mechanistic studies. It is further complemented by findings in "CAY10499 in Immunometabolic Research: Beyond Lipase Inhibition", which details innovative use-cases at the intersection of macrophage biology and metabolic regulation—areas directly informed by the reference study’s immunosuppressive TAM model.

For researchers interested in lipid signaling, CAY10499's selectivity profile surpasses less specific lipase inhibitors, minimizing confounding effects from cannabinoid receptor blockade or off-target pathways (see product data), and allowing for cleaner interpretation of results in complex biological systems.

Troubleshooting and Optimization Tips

• Solubility and precipitation: CAY10499 is insoluble in water; always prepare concentrated stocks in DMSO or ethanol, and pre-warm to 37°C to aid dissolution. Avoid exceeding 0.5% DMSO in cell-based assays to minimize cytotoxicity.
• Assay interference: For hydrolysis assays utilizing chromogenic or fluorescent substrates, verify that CAY10499 does not quench or absorb at detection wavelengths. Include vehicle and inhibitor-only controls to account for any compound interference.
• Temporal inhibition profiling: In prolonged incubations (>24 h), periodic replenishment may be necessary due to potential compound degradation; short-term exposure (1–3 h) is optimal for maximal activity as recommended by APExBIO.
• Target specificity: Confirm that observed effects on lipid accumulation or signaling are attributable to HSL/MGL inhibition by including genetic knockdown/knockout or orthogonal inhibitor controls where possible.

Why this Cross-Domain Matters, Maturity, and Limitations

The integration of lipid metabolism inhibitors like CAY10499 into immunometabolic research bridges classical metabolic biochemistry and modern immunology. The reference study's demonstration that metabolic reprogramming via EV-transferred ACLY drives monocyte-to-TAM differentiation highlights a new frontier where metabolic enzymes dictate immune cell fate and therapeutic resistance. Utilizing CAY10499 in this context enables researchers to interrogate how blocking alternative lipid hydrolysis pathways (HSL/MGL) may modulate macrophage polarization, tumor progression, or response to immunotherapies. However, while the cited study validates ACLY inhibition in HCC/TAM models, the direct translation of HSL/MGL inhibition effects on EV-driven macrophage fate requires further empirical investigation—underscoring the necessity of careful experimental design and interpretation.

Future Outlook

As the landscape of immunometabolic research expands, tools such as CAY10499 will be pivotal for dissecting the intricate connections between lipid metabolism and immune regulation. The reference study’s mechanistic insights set the stage for synergy: combining ACLY and HSL/MGL inhibition strategies may unravel new therapeutic avenues for modulating the tumor microenvironment and enhancing immunotherapy efficacy. Going forward, systematic evaluation of CAY10499's effects in TAM differentiation, foam cell formation, and metabolic disease models—using advanced lipidomics and single-cell profiling—will deepen our understanding of lipid-driven immune dynamics and inform drug discovery efforts targeting metabolic-immune axes. For those seeking a high-fidelity, validated inhibitor for lipid metabolism research, APExBIO's CAY10499 stands as a foundational reagent poised for diverse translational applications.